)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Beijing Tiantan Biological Products
Beijing Tiantan Biological Products (600161) investor relations material
Beijing Tiantan Biological Products H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary28 Aug, 2026
Executive summary
Revenue for H1 2026 was RMB 2.60 billion, down 16.56% year-over-year; net profit attributable to shareholders was RMB 298.91 million, down 52.75% year-over-year.
Gross margin for biopharmaceuticals was 35.84%, a decrease of 2.16 percentage points year-over-year.
The company maintained its leading domestic market position in blood products, with a 20% market share in plasma collection.
Dividend proposal: RMB 1 (pre-tax) per 10 shares, totaling RMB 197.74 million.
Financial highlights
Operating income: RMB 2.60 billion, down 16.56% year-over-year.
Net profit attributable to shareholders: RMB 298.91 million, down 52.75% year-over-year.
Operating cash flow: RMB 289.36 million (positive turnaround from -RMB 201.90 million in H1 2025).
Basic and diluted EPS: RMB 0.15, down 52.75% year-over-year.
Gross margin for human albumin: 29.10% (down 9.99 percentage points); for IVIG: 41.67% (up 4.84 percentage points).
Outlook and guidance
The company expects continued pressure on sales and profitability due to intensified competition, price declines, and VAT policy changes.
Long-term growth drivers include expanded clinical indications, R&D in recombinant and high-value products, and international market expansion.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Beijing Tiantan Biological Products
- Q1 profit and revenue dropped significantly on VAT and price pressures, despite subsidy gains.600161
Q1 2026 - Net profit dropped 29.59% on flat revenue as margins and cash flow declined amid policy headwinds.600161H2 2025
- Net profit fell 22.16% year-over-year despite 9.62% revenue growth, with margins under pressure.600161Q3 2025
- Revenue up 9.47%, net profit down 12.88%, with higher dividends and ongoing expansion.600161H1 2025
- Net profit rose 18.52% year-over-year, but Q3 profit declined 7.44%.600161Q3 2024
- Net profit surged 28.12% on higher margins and robust plasma business growth.600161H1 2024
- Revenue up 7.84%, but net profit down 22.90% and operating cash flow negative.600161Q1 2025
- Net profit jumped 39.42% on strong sales and plasma collection growth.600161H2 2024
Next Beijing Tiantan Biological Products earnings date
Q3 202626 Oct, 2026
Beijing Tiantan Biological Products
Next Beijing Tiantan Biological Products earnings date
Q3 202626 Oct, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage